生物制剂治疗对银屑病相关心血管疾病的影响

doi:10.35541/cjd.20200649

Abstract

Abstract: 【Abstract】 Psoriasis is prone to be accompanied by cardiovascular diseases. Psoriasis and atherosclerosis have similar pathogenesis, involving the activation of innate immunity and autoreactive T cells. In recent years, more and more biological agents have been applied to systemic treatment of psoriasis, including tumor necrosis factor-α, interleukin-12/23 inhibitors and interleukin-17A inhibitors. The efficacy and safety of different biological agents, as well as their impact on cardiovascular diseases, have also attracted the attention of dermatologists. This review summarizes the common immunological pathogenesis of psoriasis and atherosclerosis, as well as the effects of different biological agents on cardiovascular diseases and related metabolic changes.

Key words: Psoriasis, Cardiovascular diseases, Atherosclerosis, Cardiovascular events, Biological agents

Yang Qi, Zheng Jie. Effect of biologics on cardiovascular comorbidities of psoriasis[J]. Chinese Journal of Dermatology, 2023, 56(2): 165-169.doi:10.35541/cjd.20200649

References ［50］

［1］	Dattilo G, Imbalzano E, Casale M, et al. Psoriasis and cardiovascular risk: correlation between psoriasis and cardiovascular functional indices［J］. Angiology, 2018,69（1）:31⁃37. doi: 10.1177/0003319717699329.
［2］	Fernández⁃Armenteros JM, Gómez⁃Arbonés X, Buti⁃Soler M, et al. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population⁃based study［J］. J Eur Acad Dermatol Venereol, 2019,33（1）:128⁃135. doi: 10.1111/jdv.15159.
［3］	Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences［J］. Front Immunol, 2018,9:579. doi: 10.3389/fimmu.2018.00579.
［4］	Caiazzo G, Fabbrocini G, Di Caprio R, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows［J］. Front Immunol, 2018,9:1668. doi: 10.3389/fimmu.2018.01668.
［5］	Skov L, Thomsen SF, Kristensen LE, et al. Cause⁃specific mortality in patients with psoriasis and psoriatic arthritis［J］. Br J Dermatol, 2019,180（1）:100⁃107. doi: 10.1111/bjd.16919.
［6］	Egeberg A, Skov L, Joshi AA, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events［J］. J Am Acad Dermatol, 2017,77（4）:650⁃656.e3. doi: 10.1016/j.jaad.2017.06.028.
［7］	Ramezani M, Zavattaro E, Sadeghi M. Evaluation of serum lipid, lipoprotein, and apolipoprotein levels in psoriatic patients: a systematic review and meta⁃analysis of case⁃control studies［J］. Postepy Dermatol Alergol, 2019,36（6）:692⁃702. doi: 10.5114/ada.2019.91420.
［8］	Wan MT, Shin DB, Hubbard RA, et al. Psoriasis and the risk of diabetes: a prospective population⁃based cohort study［J］. J Am Acad Dermatol, 2018,78（2）:315⁃322. doi: 10.1016/j.jaad.2017. 10.050.
［9］	Kong Y, Zhang S, Wu R, et al. New insights into different adipokines in linking the pathophysiology of obesity and psoriasis［J］. Lipids Health Dis, 2019,18（1）:171. doi: 10.1186/s12944⁃019⁃1115⁃3.
［10］	Baumer Y, Ng Q, Sanda GE, et al. Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis［J］. JCI Insight, 2018,3（1）:e97179. doi: 10.1172/jci.insight.97179.
［11］	Herbert D, Franz S, Popkova Y, et al. High⁃fat diet exacerbates early psoriatic skin inflammation independent of obesity: saturated fatty acids as key players［J］. J Invest Dermatol, 2018,138（9）:1999⁃2009. doi: 10.1016/j.jid.2018.03.1522.
［12］	Schön MP. Adaptive and innate immunity in psoriasis and other inflammatory disorders［J］. Front Immunol, 2019,10:1764. doi: 10.3389/fimmu.2019.01764.
［13］	Zhang Z, Meng P, Han Y, et al. Mitochondrial DNA⁃LL⁃37 complex promotes atherosclerosis by escaping from autophagic recognition［J］. Immunity, 2015,43（6）:1137⁃1147. doi: 10.1016/j.immuni.2015.10.018.
［14］	Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T⁃cell autoantigen in psoriasis［J］. Nat Commun, 2014,5:5621. doi: 10.1038/ncomms6621.
［15］	Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease［J］. Br J Dermatol, 2013,169（5）:1066⁃1070. doi: 10.1111/bjd.12525.
［16］	Lee S, Bartlett B, Dwivedi G. Adaptive immune responses in human atherosclerosis［J］. Int J MolSci, 2020,21（23）:9322. doi: 10.3390/ijms21239322.
［17］	Raggi P, Genest J, Giles JT, et al. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions［J］. Atherosclerosis, 2018,276:98⁃108. doi: 10.1016/j.atherosclerosis. 2018.07.014.
［18］	Ye J, Wang Y, Wang Z, et al. Roles and mechanisms of interleukin⁃12 family members in cardiovascular diseases: opportunities and challenges［J］. Front Pharmacol, 2020,11:129. doi: 10.3389/fphar.2020.00129.
［19］	Allam G, Abdel⁃Moneim A, Gaber AM. The pleiotropic role of interleukin⁃17 in atherosclerosis［J］. Biomed Pharmacother, 2018,106:1412⁃1418. doi: 10.1016/j.biopha.2018.07.110.
［20］	Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular outcomes and systemic anti⁃inflammatory drugs in patients with severe psoriasis: 5⁃year follow⁃up of a Danish nationwide cohort［J］. J Eur Acad Dermatol Venereol, 2015,29（6）:1128⁃1134. doi: 10. 1111/jdv.12768.
［21］	Parisi R, Rutter MK, Lunt M, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink［J］. J Invest Dermatol, 2015,135（9）:2189⁃2197. doi: 10.1038/jid.2015.87.
［22］	Wu JJ, Joshi AA, Reddy SP, et al. Anti⁃inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis［J］. J Eur Acad Dermatol Venereol, 2018,32（8）:1320⁃1326. doi: 10. 1111/jdv.14951.
［23］	Rungapiromnan W, Mason KJ, Lunt M, et al. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study［J］. J Eur Acad Dermatol Venereol, 2020,34（4）:769⁃778. doi: 10.1111/jdv.16018.
［24］	Champs B, Degboé Y, Barnetche T, et al. Short⁃term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta⁃analysis of randomised controlled trials［J］. RMD Open, 2019,5（1）:e000763. doi: 10.1136/rmdopen⁃ 2018⁃000763.
［25］	Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL⁃12/23 mAbbriakinumab in moderate⁃to⁃severe psoriasis［J］. J Invest Dermatol, 2012,132（2）:304⁃314. doi: 10.1038/jid.2011.304.
［26］	Lee MP, Desai RJ, Jin Y, et al. Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis［J］. JAMA Dermatol, 2019,155（6）:700⁃707. doi: 10. 1001/jamadermatol.2019.0001.
［27］	Rungapiromnan W, Yiu Z, Warren RB, et al. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta⁃analysis of randomized controlled trials［J］. Br J Dermatol, 2017,176（4）:890⁃901. doi: 10.1111/bjd.14964.
［28］	Aksentijevich M, Lateef SS, Anzenberg P, et al. Chronic inflammation, cardiometabolic diseases and effects of treatment: psoriasis as a human model［J］. Trends Cardiovasc Med, 2020,30（8）:472⁃478. doi: 10.1016/j.tcm.2019.11.001.
［29］	Mehta NN, Shin DB, Joshi AA, et al. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo⁃controlled trial［J］. Circ Cardiovasc Imaging, 2018,11（6）:e007394. doi: 10.1161/ CIRCIMAGING.117.007394.
［30］	Gelfand JM, Shin DB, Alavi A, et al. A phase IV, randomized, double⁃blind, placebo⁃controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis （the VIP⁃U Trial）［J］. J Invest Dermatol, 2020,140（1）:85⁃93. doi: 10.1016/j.jid.2019.07.679.
［31］	Pirro M, Simental⁃Mendía LE, Bianconi V, et al. Effect of statin therapy on arterial wall inflammation based on 18F⁃FDG PET/CT: a systematic review and meta⁃analysis of interventional studies［J］. J Clin Med, 2019,8（1）:118. doi: 10.3390/jcm8010118.
［32］	Rivers JP, Powell⁃Wiley TM, Dey AK, et al. Visceral adiposity in psoriasis is associated with vascular inflammation by （18）F⁃Fluorodeoxyglucosepositron⁃emission tomography/computed tomography beyond cardiometabolic disease risk factors in an observational cohort study［J］. JACC Cardiovasc Imaging, 2018,11（2 Pt 2）:349⁃357. doi: 10.1016/j.jcmg.2017.08.014.
［33］	Kim BS, Lee WK, Pak K, et al. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate⁃to⁃severe psoriasis: feasibility study using （18）F⁃fluorodeoxyglucose PET/CT［J］. J Am Acad Dermatol, 2019,80（5）:1322⁃1331. doi: 10.1016/j.jaad.2018.03. 011.
［34］	Gelfand JM, Shin DB, Duffin KC, et al. A Randomized placebo⁃controlled trial of secukinumab on aortic vascular inflammation in moderate⁃to⁃severe plaque psoriasis （VIP⁃S）［J］. J Invest Dermatol, 2020,140（9）:1784⁃1793. doi: 10.1016/j.jid.2020.01. 025.
［35］	Joshi AA, Lerman JB, Dey AK, et al. Association between aortic vascular inflammation and coronary artery plaque characteristics in psoriasis［J］. JAMA Cardiol, 2018,3（10）:949⁃956. doi: 10. 1001/jamacardio.2018.2769.
［36］	Williams MC, Kwiecinski J, Doris M, et al. Low⁃attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction: results from the multicenter SCOT⁃HEART trial （Scottish computed tomography of the HEART）［J］. Circulation, 2020,141（18）:1452⁃1462. doi: 10.1161/CIRCULATIONAHA.119.044720.
［37］	Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study［J］. Cardiovasc Res, 2019,115（4）:721⁃728. doi: 10.1093/cvr/cvz009.
［38］	Oikonomou EK, Marwan M, Desai MY, et al. Non⁃invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk （the CRISP CT study）: a post⁃hoc analysis of prospective outcome data［J］. Lancet, 2018,392（10151）:929⁃939. doi: 10.1016/S0140⁃6736（18）31114⁃0.
［39］	Elnabawi YA, Oikonomou EK, Dey AK, et al. Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index［J］. JAMA Cardiol, 2019,4（9）:885⁃891. doi: 10.1001/jamacardio. 2019.2589.
［40］	Osto E, Piaserico S, Maddalozzo A, et al. Impaired coronary flow reserve in young patients affected by severe psoriasis［J］. Atherosclerosis, 2012,221（1）:113⁃117. doi: 10.1016/j.atherosclerosis.2011.12.015.
［41］	Alba BK, Greaney JL, Ferguson SB, et al. Endothelial function is impaired in the cutaneous microcirculation of adults with psoriasis through reductions in nitric oxide⁃dependent vasodilation［J］. Am J Physiol Heart CircPhysiol, 2018,314（2）:H343⁃H349. doi: 10.1152/ajpheart.00446.2017.
［42］	Piaserico S, Osto E, Famoso G, et al. Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis［J］. Atherosclerosis, 2016,251:25⁃30. doi: 10.1016/j.atherosclerosis.2016.05.036.
［43］	Choi H, Uceda DE, Dey AK, et al. Application of non⁃invasive imaging in inflammatory disease conditions to evaluate subclinical coronary artery disease［J］. Curr Rheumatol Rep, 2019,22（1）:1. doi: 10.1007/s11926⁃019⁃0875⁃0.
［44］	Von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks［J］. J Invest Dermatol, 2019,139（5）:1054⁃1062. doi: 10.1016/j.jid.2018.10. 042.
［45］	Groenendyk JW, Shukla P, Dey AK, et al. Association of aortic vascular uptake of （18）FDG by PET/CT and aortic wall thickness by MRI in psoriasis: a prospective observational study［J］. Eur J Nucl Med Mol Imaging, 2019,46（12）:2488⁃2495. doi: 10.1007/s00259⁃019⁃04454⁃w.
［46］	Vlachopoulos C, Gravos A, Georgiopoulos G, et al. The effect of TNF⁃a antagonists on aortic stiffness and wave reflections: a meta⁃analysis［J］. Clin Rheumatol, 2018,37（2）:515⁃526. doi: 10.1007/s10067⁃017⁃3657⁃y.
［47］	Eder L, Joshi AA, Dey AK, et al. Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease［J］. Arthritis Rheumatol, 2018,70（3）:408⁃416. doi: 10.1002/art.40366.
［48］	Hjuler KF, Bøttcher M, Vestergaard C, et al. Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis［J］. JAMA Dermatol, 2016,152（10）:1114⁃1121. doi: 10.1001/jamadermatol.2016.1984.
［49］	Toussirot E. The interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition［J］. Metabolites, 2020,10（3）. doi: 10.3390/metabo10030107.
［50］	Takamura S, Takahashi A, Inoue Y, et al. Effects of tumor necrosis factor⁃α, interleukin⁃23 and interleukin⁃17A inhibitors on bodyweight and body mass index in patients with psoriasis［J］. J Dermatol, 2018,45（9）:1130⁃1134. doi: 10.1111/1346⁃8138.14526.

[1]	He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.
[2]	Yuan Chen, Yan Yan, Wang Baoxi . Biotherapy for acne inversa [J]. Chinese Journal of Dermatology, 2023, 56(3): 270-273.
[3]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[4]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.
[5]	Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215.
[6]	Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2022 [J]. Chinese Journal of Dermatology, 2023, 56(3): 266-269.
[7]	Ruan Shifan, Zhang Peng, Lin Tingting, Luo Renwei, Bao Siyi, Xue Chenyao, Tong Zequn, Zhang Liangliang, Gong Ting, Ji Chao, . Correlations between psoriasis vulgaris and dyslipidemia [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220322-e20220322.
[8]	Tian Jing, Liang Yuan, Ma Lin. Dupilumab in the treatment of childhood atopic dermatitis [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210730-e20210730.
[9]	Chen Lianghong, Sun Yan, Wang Jingyu, Wu Yan. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210875-e20210875.
[10]	Wang Zhaoyang, Xiang Xin, Chen Yunliu, Miao Chaoyang, Zhao Xinrong, Zhang Zhenhua, Liu Yuanxiang, Ma Lin, Xu Zigang. Comparison of efficacy and safety of biologics versus methotrexate in the treatment of severe pediatric plaque psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 112-117.
[11]	Jia Yuanyuan, Mao Qiuyu, Yang Jingyi, Min Wei. Efficacy of dupilumab in the treatment of moderate and severe atopic dermatitis in the elderly: a clinical observation [J]. Chinese Journal of Dermatology, 2023, 56(2): 125-129.
[12]	Huang He, Zhang Xuejun. Application of the interleukin-23 inhibitor guselkumab in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 181-184.
[13]	Yang Ying, Guo Qing, Hou Suchun, Min Xue, Tian Jiabin, Qiao Zhuhui, Lin Jialin, Wang Xiaofei, Wu Lantuya, Zhang Zhenying, Li Zhengfeng, Wang Bin, Liu Xiaoming. COVID-19 vaccination status and its impact on psoriatic lesions in patients with psoriasis treated with biologics: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2023, 56(1): 59-63.
[14]	Zheng Jiayuan, Yu Bingqian, Chen Xianxia, Luo Zhicheng. Characteristics of pruritus in adult patients with psoriasis vulgaris and its effect on quality of life [J]. Chinese Journal of Dermatology, 2022, 55(9): 790-794.
[15]	Xiao Chunying, Wang Gang. Roles of Langerhans cells in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 830-834.

Effect of biologics on cardiovascular comorbidities of psoriasis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［50］

Related Articles 15

Metrics

Comments

Recommended 10